A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers
Latest Information Update: 25 May 2022
At a glance
- Drugs Zolunicant (Primary)
- Indications Leishmaniasis; Opioid-related disorders; Substance-related disorders
- Focus Adverse reactions
- Sponsors Mindmed
- 19 May 2022 Results presented in a MindMed media release.
- 28 Mar 2022 According to a MindMed media release, topline data from this trial is expected in Q2 2022
- 04 Jan 2022 According to a MindMed media release, results from this study will inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal